Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

The goal of this clinical trial is to to learn about different combinations of immunotherapy in patients with colorectal cancer whose cancer has spread to their liver and are planning to have surgery to remove tumor metastases from their liver. The main questions it aims to answer are: * whether these combinations of immunotherapy change the tumor microenvironment in the liver * whether these combinations of immunotherapy are safe and effective when used in colorectal cancer with liver metastases Participants will be randomly assigned to one of the following: * Botensilimab and balstilimab

Trial Details

NCT ID
NCT06300463
Phase
PHASE2
Sponsor
Weill Medical College of Cornell University
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Botensilimab
  • Balstilimab
  • AGEN1423
  • Radiation
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Diagnosis of metastatic colorectal adenocarcinoma with liver metastases
  • Participant must be planning to undergo a surgical resection of their liver metastases.
  • Tumor is non-MSI-H/dMMR
  • Presence of measurable disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →